BioSpace News Archive

MyoKardia, Inc., presented data at the European Society of Cardiology Heart Failure Congress from its Phase 1a single-ascending dose study of MYK-491 in healthy volunteers.

“Reaching this pre-specified clinical endpoint is an important milestone that brings us one step closer to a potential regulatory submission in both the U.S. and Europe for valoctocogene roxaparvovec to treat adults with severe hemophilia A,” stated Hank Fuchs, president of Worldwide Research and Development at BioMarin.

Eli Lilly announced it has inked a license agreement with Centrexion Therapeutics to acquire the exclusive global rights to CNTX-0290.

Expending countless hours of time and energy usually leads to frustration and burnout during a job search. Here are some tips to understanding what a company is really looking for in a job description.

With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.

Addressing a billion-dollar market with innovative technologies which remove bottlenecks in research and discovery

Domain Therapeutics announces that it has secured a €3.5M investment from existing shareholder Seventure Partners, to accelerate its next growth phase.

Genovis expands its portfolio of glycan specific enzymes with the launch of SialEXO 23. A new member of the SialEXO family, SialEXO 23 is an enzyme for study of a specific type of sugar on biopharmaceuticals.

Esperion announced that the company will participate in analyst-led fireside chats with investors at the following conferences

TARA Biosystems, Inc. announced the execution of an exclusive worldwide license agreement with Columbia University for intellectual property relating to engineered human heart tissues.